Last updated: February 26, 2026
What is NDC 60505-2648?
NDC 60505-2648 refers to Pfizer's drug Vyndaqel (tafamidis meglumine), a medication approved for treating transthyretin amyloid cardiomyopathy (ATTR-CM). It was approved by the FDA in May 2019. The drug acts as a transthyretin stabilizer, preventing amyloid fibril formation, which impairs heart function.
Market Overview
Therapeutic Focus and Patient Population
Vyndaqel primarily treats ATTR-CM, a rare, progressive, and often fatal disease. The disease affects an estimated 50,000 to 100,000 patients globally, with higher prevalence in older males.
Competitive Landscape
- Main Competitor: Efim programs for ATTR-CM include treatments like daratumumab (experimental) and off-label use of other heart failure drugs.
- Pipeline Drugs: Several candidates are in development, including plant-based stabilizers and gene-silencing therapies.
- Market Entry Barriers: High uncertainties in early-stage pipeline drugs and limited diagnostics for early detection hinder market growth.
Market Dynamics
- Growth Drivers:
- Increasing disease awareness.
- Expanded diagnostic capabilities.
- Broader FDA label approvals covering additional patient segments.
- Challenges:
- High drug cost.
- Limited payer coverage due to rarity.
- Long-term safety data still accruing.
Price History and Current Pricing
Launch Pricing
- In the U.S.: Approximate wholesale acquisition cost (WAC) at launch in 2019 was $50,000 per year per patient.
- Recent Trends: The price has increased gradually, reaching approximately $55,000–$60,000 annually in 2022.
Comparative Pricing
| Brand Name |
Approximate Annual Cost |
Indication |
Notes |
| Vyndaqel |
$55,000–$60,000 |
ATTR-CM |
FDA approved, first-line |
| Other drugs* |
Varies |
Rare |
Under development, off-label |
*Note: No direct commercial competitors approved for ATTR-CM currently.
Key Market Projections (2023-2028)
| Year |
Estimated Global Patients |
Estimated Revenue |
Key Assumptions |
| 2023 |
7,000 |
$385 million |
7,000 patients, $55,000 per patient annually |
| 2024 |
8,500 |
$468 million |
Adoption driven by increased awareness |
| 2025 |
10,000 |
$550 million |
Expanded diagnostics and label expansion |
| 2026 |
12,000 |
$660 million |
Broader coverage, longer patient survival |
| 2027 |
14,000 |
$770 million |
Entry of pipeline drugs, increased uptake |
| 2028 |
16,000 |
$880 million |
Market maturation, off-label use increase |
Underlying Assumptions:
- Annual patient growth rate of approximately 20% through 2025, slowing to 10% thereafter.
- Price stabilization within ±10% range.
- No significant price reductions due to payer negotiations.
Pricing Sensitivity Analysis
| Scenario |
Price Adjustment |
Impact on Revenue |
| Base case |
$55,000/year |
$385M (2023) |
| Price reduction of 10% |
$49,500/year |
$344.5M (2023) |
| Price increase of 10% |
$60,500/year |
$424.5M (2023) |
| Launching generic alternatives |
20-30% price reduction |
Potential decline in revenue if generics penetrate early |
Future Price Outlook
- Short-term: Price stability expected due to limited alternatives.
- Mid-term (2025-2030): Possible price erosion from biosimilar or generic competition, with potential 20–30% reduction.
- Long-term: Market saturation and increased competition could halve current prices unless new indications or formulations are approved.
Critical Factors Impacting Pricing and Market Penetration
- Regulatory approvals for expanded indications.
- Payer acceptance and insurance coverage.
- Advances in diagnostics leading to earlier detection.
- Development of effective alternative therapies or biosimilars.
Summary
Vyndaqel dominates the emerging ATTR-CM market, with steady revenue growth supported by increasing diagnoses and broader approval. Its pricing remains high due to the rare disease context, but future pressures may necessitate adjustments driven by competition and market dynamics.
Key Takeaways
- NDC 60505-2648 (Vyndaqel) is the first approved therapy for ATTR-CM, with annual prices around $55,000–$60,000.
- The market is expected to grow to over $880 million globally by 2028, with a patient base expanding due to better diagnostics.
- Price stability is likely in the near term; long-term pricing may decline with biosimilar competition, depending on regulatory and market developments.
- The key growth drivers include increased disease awareness, expanded diagnostics, and potential new indications.
- Market challenges include payer restrictions, high drug costs, and uncertainty about pipeline drug efficacy.
Frequently Asked Questions
1. How has the pricing of Vyndaqel evolved since its launch?
The annual wholesale price increased from approximately $50,000 in 2019 to around $55,000–$60,000 in 2022, reflecting minor adjustments rather than significant hikes.
2. What is the potential impact of biosimilars or generics on Vyndaqel pricing?
Price reductions between 20% and 30% could occur if biosimilar competitors enter the market, especially after patent expiration or loss of exclusivity.
3. What factors could accelerate market growth beyond projections?
Greater awareness, improved diagnostic techniques, and FDA approval for additional indications could expand the patient pool and revenue.
4. How does the patient population estimate account for disease prevalence?
The estimate of 7,000–16,000 patients accounts for diagnosed cases, expected diagnosis rate increases, and growth in screening practices.
5. What are the risks associated with future price projections?
Market entry of competitors, regulatory changes, or broader insurance coverage limitations could reduce prices and slow revenue growth.
References
[1] U.S. Food and Drug Administration. (2019). FDA approves first transthyretin amyloid cardiomyopathy drug. [Press release].
[2] EvaluatePharma. (2022). Market forecast for rare disease therapies.
[3] IQVIA. (2022). Global pharmaceutical pricing trends.
[4] EMA. (2021). Efficacy and safety data for tafamidis in ATTR-CM.
[5] World Health Organization. (2021). Rare disease prevalence estimates.
